Amgen To Defend Neulasta Against Biosimilars With New Delivery System
This article was originally published in The Pink Sheet Daily
Executive Summary
A novel on-body delivery system for Neulasta, pending at FDA for approval, could ease administration for patients and help Amgen protect its blockbuster neutropenia franchise against biosimilars.
You may also be interested in...
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.
Regeneron Oncology Setback Delivered By US FDA Crackdown On Accelerated Approval
The company received two complete response letters from the US FDA for the CD20xCD3 bispecific antibody odronextamab due to clinical trial requirements for accelerated approval.